
USA - NASDAQ:TOCA -
The current stock price of TOCA is 1.26 null. In the past month the price increased by 6.78%. In the past year, price decreased by -79.24%.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States.
Tocagen Inc
4242 CAMPUS POINT COURT SUITE 500
SAN DIEGO CA 92121
CEO: Martin J. Duvall
Phone: 858-412-8400
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States.
The current stock price of TOCA is 1.26 null. The price decreased by -3.82% in the last trading session.
TOCA does not pay a dividend.
TOCA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
TOCA stock is listed on the Nasdaq exchange.
Tocagen Inc (TOCA) has a market capitalization of 30.14M null. This makes TOCA a Nano Cap stock.
ChartMill assigns a technical rating of 4 / 10 to TOCA. When comparing the yearly performance of all stocks, TOCA is a bad performer in the overall market: 98.05% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to TOCA. Both the profitability and financial health of TOCA have multiple concerns.
Over the last trailing twelve months TOCA reported a non-GAAP Earnings per Share(EPS) of -2.69. The EPS decreased by -10.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -210044.44% | ||
| ROA | -304.38% | ||
| ROE | N/A | ||
| Debt/Equity | 1.88 |